Catalent Pharma Solutions and CTC Bio have entered into a collaboration to provide services to South Korean pharma companies looking to commercialize solid oral dose and controlled release products in the U.S. and Europe. The companies will leverage their expertise in drug delivery technologies to give South Korean customers access to global markets for their products and formulations.
“South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations,” said Dr. HR Jeon, chief science officer of CTC Bio. “This collaboration with Catalent provides South Korean pharma customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities. Catalent's breadth of services and reputation for successful new product launches in international markets makes them an ideal partner for us and our clients/partners in South Korea.”
Ian Muir, president of Catalent’s Modified Release Technologies business, said, “CTC Bio is a leading regional provider of innovative drug products and formulation services and its capabilities perfectly complement those of Catalent. In collaboration with CTC Bio, Catalent can now provide South Korean pharmaceutical customers with seamless scale-up and transfer within Catalent’s controlled release capabilities at our Winchester, KY and Somerset, NJ facilities in the U.S. and at Schorndorf, Germany in Europe. These are leading commercial facilities for oral solids and controlled release dosage forms, ensuring that commercial manufacture for global supply is carried within the target markets and meets all international standards of quality and reliability.”